The β2-adrenergic receptor and Her2 comprise a positive feedback loop in human breast cancer cells

被引:0
|
作者
Ming Shi
Dan Liu
Huijun Duan
Lu Qian
Lina Wang
Lijia Niu
Huipeng Zhang
Zheng Yong
Zehui Gong
Lun Song
Ming Yu
Meiru Hu
Qing Xia
Beifen Shen
Ning Guo
机构
[1] Institute of Basic Medical Sciences,Department of Molecular Immunology
[2] Hebei Medical University,Department of Pathology
[3] People’s Armed Police Corps Hospital,Department of the Obstetrics and Gynecology
[4] The Laboratory of Evaluation for New Drug,undefined
[5] Institute of Pharmacology and Toxicology,undefined
来源
关键词
β2-AR; Her2; STAT3; ERK; Breast cancer;
D O I
暂无
中图分类号
学科分类号
摘要
In this study, β2-AR level was found to be up-regulated in MCF-7 cells overexpressing Her2 (MCF-7/Her2). Correlation of β2-AR level with Her2 status was demonstrated in breast cancer tissue samples. Constitutive phosphorylation of ERK, mRNA expression up-regulation of catecholamine-synthesis enzymes, and increased epinephrine release were detected in MCF-7/Her2 cells. β2-AR expression induced by epinephrine and involvement of ERK signaling were validated. The data indicate that Her2 overexpression and excessive phosphorylation of ERK cause epinephrine autocrine release from breast cancer cells, resulting in up-regulation of β2-AR expression. The data also showed that catecholamine prominently stimulated Her2 mRNA expression and promoter activity. The activation and nuclear translocation of STAT3 triggered by isoproterenol were observed. Enhanced binding activities of STAT3 to the Her2 promoter after isoproterenol stimulation were verified. Using STAT3 shRNA and dominant negative STAT3 mutant, the role of STAT3 in isoproterenol-induced Her2 expression was further confirmed. The data support a model where β2-AR and Her2 comprise a positive feedback loop in human breast cancer cells.
引用
收藏
页码:351 / 362
页数:11
相关论文
共 50 条
  • [21] The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells
    Sahlberg, Kristine Kleivi
    Hongisto, Vesa
    Edgren, Henrik
    Makela, Rami
    Hellstrom, Kirsi
    Due, Eldri U.
    Vollan, Hans Kristian Moen
    Sahlberg, Niko
    Wolf, Maija
    Borresen-Dale, Anne-Lise
    Perala, Merja
    Kallioniemi, Olli
    MOLECULAR ONCOLOGY, 2013, 7 (03) : 392 - 401
  • [22] CCN5 down regulates HER2/neu expression in HER2 positive breast cancer cells
    Sarkar, Sandipto
    Maity, Gargi
    Das, Amlan
    Majumder, Monami
    Banerjee, Snigdha
    Banerjee, Sushanta
    CANCER RESEARCH, 2015, 75
  • [23] Personalized medicine for HER2 positive breast cancer
    Tamura, Kenji
    ANNALS OF ONCOLOGY, 2016, 27
  • [24] Characterization of HER2 positive breast cancer in Tunisia
    Yaiche, R.
    Houcine, Y.
    Saidi, E.
    Saadallah, F.
    Kamoun, S.
    Meddeb, K.
    Driss, M.
    VIRCHOWS ARCHIV, 2024, 485 : S210 - S210
  • [25] Delayed chemotherapy in HER2 positive breast cancer
    Hur, Ho
    Le, Amy
    Chang, Helena R.
    CANCER RESEARCH, 2020, 80 (04)
  • [26] Treatment of HER2 positive breast cancer patients
    Matos, Erika
    ZDRAVNISKI VESTNIK-SLOVENIAN MEDICAL JOURNAL, 2012, 81 (03): : 236 - 245
  • [27] HER2 POSITIVE BREAST CANCER - BIOLOGY AND RESISTANCE
    Penault-Llorca, Frederique
    BREAST, 2019, 48 : S31 - S31
  • [28] Adjuvant therapy in breast cancer HER2 positive
    Olivito, V.
    De Simone, R.
    La Gattuta, G.
    Lucia, M.
    Dima, G.
    Talarico, R.
    Filippelli, G.
    ANNALS OF ONCOLOGY, 2006, 17 : VII146 - VII146
  • [29] EARLY RELAPSE OF HER2 POSITIVE BREAST CANCER
    Zelen, Teodora Brdar
    Prica, Anja
    Jovisevic, Marija
    BREAST, 2023, 71 : S58 - S58
  • [30] Targeted therapy for HER2 positive breast cancer
    Jason A Incorvati
    Shilpan Shah
    Ying Mu
    Janice Lu
    Journal of Hematology & Oncology, 6